Literature DB >> 16497941

Unexpected serum parathyroid hormone profiles in some patients with primary hyperparathyroidism.

Philippe Boudou1, Fidaa Ibrahim, Catherine Cormier, Emile Sarfati, Jean-Claude Souberbielle.   

Abstract

BACKGROUND: Third-generation parathyroid hormone (PTH) assays have been reported to measure only intact PTH(1-84), in contrast to second-generation assays, which also detect PTH(7-84) fragments. Higher PTH measurements were observed with third- than with second-generation PTH assays in a few patients with either severe primary hyperparathyroidism or parathyroid carcinoma.
METHODS: We analyzed biological data [second- and third-generation PTH assays, 25-hydroxyvitamin D (25-OHD), calcium, and phosphate concentrations] obtained before and after surgery for 2 groups of patients selected from a large series of consecutive patients with primary hyperparathyroidism (PHPT): 7 female patients with surgically and histologically confirmed PHPT (group 1) and a matched group (group 2).
RESULTS: For group 1 but not group 2, PTH concentrations measured by third-generation PTH assays before surgery were higher than those measured by the second-generation assays. Circulating 25-OHD, calcium, and phosphate concentrations were similar in both groups. In addition, PTH values measured with the third-generation PTH assays in group 1 decreased after surgery.
CONCLUSIONS: Our results confirm that third-generation PTH assays do not measure only PTH(1-84). The frequency of this unexpected finding of markedly lower PTH concentrations than previously reported was approximately 5% in patients with PHPT without malignancy. We do not know whether the presence of this unexpected profile is predictive of malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497941     DOI: 10.1373/clinchem.2005.060962

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

Review 1.  Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism.

Authors:  J C Souberbielle; P Boudou; C Cormier
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

2.  Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation.

Authors:  Philippe Caron; William F Simonds; Jean-Christophe Maiza; Mishaela Rubin; Tom Cantor; Louise Rousseau; John P Bilezikian; Jean-Claude Souberbielle; Pierre D'Amour
Journal:  Clin Endocrinol (Oxf)       Date:  2011-06       Impact factor: 3.478

3.  Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy.

Authors:  Philippe Boudou; Fidaa Ibrahim; Catherine Cormier; Emile Sarfati; Jean-Claude Souberbielle
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

4.  Full-length versus intact PTH concentrations in pseudohypoparathyroidism type 1 and primary hyperparathyroidism: clinical evaluation of immunoassays in individuals from China.

Authors:  Yi Yang; Ailing Song; An Song; Yingying Hu; Yan Jiang; Mei Li; Weibo Xia; Xiaoping Xing; Xinqi Cheng; Ou Wang
Journal:  Endocrine       Date:  2022-10-11       Impact factor: 3.925

5.  Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-Jing Wang; Shobha Sahney; Barbara Gales; Robert M Elashoff; Harald Jüppner; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2009-03-20       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.